News

The Phase 1/2 trial will be conducted initially in normal healthy volunteers, and, then, in patients with PH1. Initiation of this trial is based on encouraging pre-clinical data

ImmuPharma is pleased to confirm that the first European site in Bordeaux, France is open and the patient recruitment process in Europe has now commenced. This follows on

Medivation can now go ahead with the phase II clinical trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and other studies that cross refer

MEDI-551 is an anti-CD19 monoclonal antibody indicated to treat neuromyelitis optica and neuromyelitis optica spectrum disorders. The drug is presently in phase IIb clinical development for treating NMO,

Submission of the MAA for Xilonix is necessary for the Company to gain approval to sell the drug in European Union member nations. The Company, which only recently

Proceeds will be used to advance the company’s immunotherapy programs. These programs include its lead drug candidate, an anti-CCR4 monoclonal antibody for the treatment of cancer, which is

The company expects to report top-line data from the study in the third quarter of this year. Under the phase 2 ReVEAL study, the company will assess the

The trial was a pivotal Phase 2/3 study designed to evaluate KEYTRUDA compared to chemotherapy based on prospective measurement of PD-L1 expression in previously treated patients with advanced

"CDI results from damage to the microbiome, and patients experience further collateral damage through the use of broad spectrum antibiotics to treat CDI, leaving them vulnerable to recurrent